Cylon Pharmaceuticals grabs over 1 billion injections Mentoine paraceanin injectionapproves approved

Medical Network May 18 hearing May 14, sialon Pharmaceutical announced that a wholly owned subsidiary of Hunan Pharmaceutical sialon get ornithine aspartate injection SFDA approved recently issued " drug registration approval document" Meters within the network data show that in 2019 Chinese public medical institutions terminal aspartate ornithine injections overall sales of over one billion yuan, Wuhan Kai Rui Pharmaceutical exclusive Bacheng marketornithine aspartate belongs liver medication injection, apply due to acute, chronic liver disease (e.g., various types of hepatitis, cirrhosis, fatty liver, hepatitis after syndrome) triggered ammonia liter high and treatment of hepatic encephalopathy, such as secondary to or associated with liver detoxification function is impaired (such as cirrhosis) or the potential for exacerbation of hepatic encephalopathy, especially for the treatment of hepatic coma or hepatic coma early awareness of the fuzzy stateFigure 1: 2015--2019 China's public sector sales terminal aspartic acid ornithine injection (unit: million)currently marketed domestic market ornithine aspartate aspartate injection has ornithine injection and injection ornithine aspartateMeters within the network data show that in 2019 China urban public, county public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal aspartic acid ornithine injection sales of 1.144 billion yuan, year on year decline last yearFigure 2: 2019 Chinese public medical institutions terminal aspartic competition ornithine injectionMaxwell, Qingdao Jinfeng, Fuan Pharmaceutical Qingyu Tang Pharmaceutical, SPG Silver Lake, sialon Pharmaceutical five pharmaceutical companies have ornithine aspartate injection production approval, Wuhan Kai Rui Pharmaceutical exclusive ornithine aspartate injection production approval2019 Chinese public medical institutions terminal aspartic competition ornithine injections, Wuhan Kai Rui medicine to 81.77% of market share in the first qualifying session, Maxwell to 17.79% market share immediately thereafter, both combined market share of over 90%3 layout pharmaceutical companies ornithine aspartate injection consistency in evaluation, which Xinghao Guangdong medicine, to imitate Southwest Pharmaceutical packet 4 based production, after the production deemed granted by consistency evaluation, Fuan pharmaceutical Qingyu Tang pharmaceutical product consistency that filed a supplemental application evaluationNote: Statistics as of May 15, if imperfect, please correct me!